Stock Track | HJ SCIENCE-B Plummets 5.01% Intraday as Clinical-Stage Biotech Debuts with No Revenue or Approved Products

Stock Track

06/23

HJ SCIENCE-B (06132) saw its stock price plummet 5.01% during intraday trading on Tuesday, shortly after its debut on the Hong Kong exchange.

The company is a clinical-stage biotechnology firm with three core products—HJ787, HJ178, and HJ891—all classified as Category 1 innovative drugs but still awaiting regulatory approval. According to its prospectus, HJ SCIENCE-B has not yet received approval for the commercial sale of any products and has generated no revenue from product sales to date.

Investor sentiment appeared cautious as the market assessed the company's early-stage development status and lack of commercial track record, despite its integrated drug development platform covering everything from drug design to clinical studies.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1169390619"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1169390619\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1169390619?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-23 09:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1169390619","market":"sg","top_or_hot":-1,"title":"Stock Track | HJ SCIENCE-B Plummets 5.01% Intraday as Clinical-Stage Biotech Debuts with No Revenue or Approved Products","media":"Stock Track","content":"<p>HJ SCIENCE-B (06132) saw its stock price plummet 5.01% during intraday trading on Tuesday, shortly after its debut on the Hong Kong exchange.</p><p>The company is a clinical-stage biotechnology firm with three core products—HJ787, HJ178, and HJ891—all classified as Category 1 innovative drugs but still awaiting regulatory approval. According to its prospectus, HJ SCIENCE-B has not yet received approval for the commercial sale of any products and has generated no revenue from product sales to date.</p><p>Investor sentiment appeared cautious as the market assessed the company's early-stage development status and lack of commercial track record, despite its integrated drug development platform covering everything from drug design to clinical studies.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | HJ SCIENCE-B Plummets 5.01% Intraday as Clinical-Stage Biotech Debuts with No Revenue or Approved Products</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | HJ SCIENCE-B Plummets 5.01% Intraday as Clinical-Stage Biotech Debuts with No Revenue or Approved Products\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-06-23 09:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HJ SCIENCE-B (06132) saw its stock price plummet 5.01% during intraday trading on Tuesday, shortly after its debut on the Hong Kong exchange.</p><p>The company is a clinical-stage biotechnology firm with three core products—HJ787, HJ178, and HJ891—all classified as Category 1 innovative drugs but still awaiting regulatory approval. According to its prospectus, HJ SCIENCE-B has not yet received approval for the commercial sale of any products and has generated no revenue from product sales to date.</p><p>Investor sentiment appeared cautious as the market assessed the company's early-stage development status and lack of commercial track record, despite its integrated drug development platform covering everything from drug design to clinical studies.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06132","symbol_name":"华健未来-B","start_time":0,"source_url":"","article_id":"1169390619","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169390619","pubTimestamp":1782178468,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"HJ SCIENCE-B (06132) saw its stock price plummet 5.01% during intraday trading on Tuesday, shortly after its debut on the Hong Kong exchange.The company is a clinical-stage biotechnology firm with...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06132":"华健未来-B"},"translate_title":"个股追踪|HJ SCIENCE-B盘中暴跌5.01%，临床阶段生物技术首次亮相无营收或获批产品","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06132":1},"content_text":"HJ SCIENCE-B (06132) saw its stock price plummet 5.01% during intraday trading on Tuesday, shortly after its debut on the Hong Kong exchange.The company is a clinical-stage biotechnology firm with three core products—HJ787, HJ178, and HJ891—all classified as Category 1 innovative drugs but still awaiting regulatory approval. According to its prospectus, HJ SCIENCE-B has not yet received approval for the commercial sale of any products and has generated no revenue from product sales to date.Investor sentiment appeared cautious as the market assessed the company's early-stage development status and lack of commercial track record, despite its integrated drug development platform covering everything from drug design to clinical studies.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}